Guidance - Page 4 of 5 - The British Society of Gastroenterology

Guidance

First published on 27 Oct 2015

UK Key Performance Indicators and Quality Assurance Standards for Colonoscopy

Authors Rees CJ, Thomas-Gibson S, Rutter MD, Baragwanath P, Pullan R, Feeney M, Haslam N. Colonoscopy is the ‘gold standard’ investigation for assessment of the large bowel allowing diagnosis, biopsying, and therapy to be undertaken. Colonoscopy detects and prevents colorectal […]

Guidance

First published on 25 Oct 2015

NICE guidance on Ombitasvir–Paritaprevir–Ritonavir with or without Dasabuvir for treating chronic hepatitis C

NICE technology appraisal guidance [TA365] Published date: November 2015

Guidance

First published on 22 Oct 2015

NHS England service specification for Operational Delivery Networks for hepatitis C care in adults

22nd October 2015 NHS England has published the service specification for Operational Delivery Networks (ODNs) for hepatitis C care in adults. The full document is available below. Many BSG members will have been involved in the set up processes to date […]

Guidance

First published on 26 Aug 2015

Vedolizumab for the treatment of adult patients with moderately to severely active Crohn’s disease

Vedolizumab (Entyvio) is recommended. It is a possible option for adults with moderate to severe Crohn’s disease if a tumour necrosis factor (TNF)-alpha inhibitor isn’t suitable or hasn’t worked well enough. People should be able to have vedolizumab until it […]

Guidance

First published on 22 Jul 2015

NICE guidance on Naloxegol for treating opioid-induced constipation

Naloxegol is recommended, within its marketing authorisation, as an option for treating opioid induced constipation in adults whose constipation has not adequately responded to laxatives. An inadequate response is defined as opioid-induced constipation symptoms of at least moderate severity in […]

Guidance

First published on 05 Jun 2015

NICE Guidance on vedolizumab for treating moderately to severely active ulcerative colitis

June 2015 Vedolizumab (Entyvio) is recommended by NICE as a possible treatment for adults with moderate to severe ulcerative colitis. People should be able to have the treatment until it stops working or surgery is needed. Their condition should be […]

Guidance

First published on 25 Feb 2015

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

February 2015 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) Infliximab (also known as Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) […]

Guidance

First published on 01 Jul 2014

The practical management of the gastrointestinal symptoms of pelvic radiation disease

Misc authors July 2014 A new report from Jervoise Andreyev and his team at the Marsden was published as an open access article in Frontline Gastroenterology and can be found via the link below. Macmillan funded the design and print […]

Guidance

First published on 01 Jun 2014

ERCP – The Way Forward, A Standards Framework

Author Mark Wilkinson, (BSG Endoscopy, working party convenor and chairman) et al. June 2014 Executive Summary To improve the quality and availability of ERCP in the UK, a working party was set up incorporating a number of stakeholders (Appendix 3) to […]

Guidance

First published on 01 Oct 2013

NICE Diagnostics Guidance: Faecal Calprotectin Diagnostic Tests for IBD

Faecal calprotectin testing is recommended as an option to support clinicians with the differential diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) in adults with recent onset lower gastrointestinal symptoms for whom specialist assessment is being considered, […]